
Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.
-
2016 - Founded
-
2018 - Partnered, Series A
-
2022 - IPO; NASDAQ: SNTI

